产品说明书

9-Aminocamptothecin

Print
Chemical Structure| 91421-43-1 同义名 : 9-Amino-20(S)-camptothecin;9-Amino-CPT;NSC 603071;Aminocamptothecin;9-AC
CAS号 : 91421-43-1
货号 : A432426
分子式 : C20H17N3O4
纯度 : 99%+
分子量 : 363.367
MDL号 : MFCD00909855
存储条件：

粉末 Keep in dark place,Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 3 mg/mL(8.26 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 9-Aminocamptothecin, an inhibitor of topoisomerase I, exhibits strong anticancer properties. In cancer cell lines from such as breast (MCF-7), bladder (MGH-U1), and colon (HT-29), the cytotoxic effects of 9-Aminocamptothecin escalate with increased drug concentrations and prolonged exposure periods. Notably, minimal cell death occurs unless the concentration of 9-Aminocamptothecin surpasses a threshold of 2.7 nM[1]. 9-Aminocamptothecin demonstrates inhibition of PC-3, PC-3M, DU145, and LNCaP cells, with IC50 values of 34.1 nM, 10 nM, 6.5 nM, and 8.9 nM respectively, following a drug exposure period of 96 hours[2].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00003551 Kidney Cancer Phase 2 Completed - United States, Georgia ... 展开 >> Emory University Hospital - Atlanta Atlanta, Georgia, United States, 30322 Emory University School of Medicine Atlanta, Georgia, United States, 30322 收起 <<
NCT00003523 Ovarian Cancer ... 展开 >> Primary Peritoneal Cavity Cancer 收起 << Phase 2 Completed - -
NCT00002635 Lymphoma Phase 2 Completed - United States, Connecticut ... 展开 >> Yale Comprehensive Cancer Center New Haven, Connecticut, United States, 06520-8028 United States, Illinois Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois, United States, 60611 United States, Massachusetts New England Medical Center Hospital Boston, Massachusetts, United States, 02111 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.75mL

0.55mL

0.28mL

13.76mL

2.75mL

1.38mL

27.52mL

5.50mL

2.75mL
参考文献

[1]Li ML, et al. Pharmacological determinants of 9-aminocamptothecin cytotoxicity. Clin Cancer Res. 2001 Jan;7(1):168-74.

[2]de Souza PL, et al. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. Clin Cancer Res. 1997 Feb;3(2):287-94.

[3]Jeha S, et al. Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia. Leuk Lymphoma. 1998 Dec;32(1-2):159-64.